Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lgc Genomics LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The record identifies 2 distinct examiners and 2 distinct art units, showing that prosecution activity spans multiple examination channels.
MYERS, CARLA J is the busiest examiner, with 1 pending action. Counsel should coordinate responses across the two examination paths and keep the issues assigned to each examiner distinct.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610724 | CAPTURE AND ANALYSIS OF TARGET GENOMIC REGIONS | MYERS, CARLA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610724 | CAPTURE AND ANALYSIS OF TARGET GENOMIC REGIONS | MYERS, CARLA J | — |
| 17513932 | FLEXIBLE AND HIGH-THROUGHPUT SEQUENCING OF TARGETED GENOMIC REGIONS | WOOLWINE, SAMUEL C | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17610724 | CAPTURE AND ANALYSIS OF TARGET GENOMIC REGIONS | MYERS, CARLA J | 1682 | §103§112 | Non-Final OA | — | Pending | Nov 12, 2021 |
| 17513932 | FLEXIBLE AND HIGH-THROUGHPUT SEQUENCING OF TARGETED GENOMIC REGIONS | WOOLWINE, SAMUEL C | 1681 | §103 | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLgc Genomics LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Carla J Myers has the most, with 1 of Lgc Genomics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
